Pharmaceutical Consulting

Navigating pharmaceutical markets across China and the Asia-Pacific region requires more than ambition. With complex regulatory frameworks, evolving pricing systems, and competitive dynamics, companies need more than just local presence, they need a partner with deep industry knowledge, robust strategy, and executional strength.

Cisema offers pharmaceutical consulting services that help companies in the pharmaceutical industry, including biotech, gene therapy, and life sciences innovators, prepare for market entry, accelerate approvals, and optimize commercialization across the region. We support clients with a comprehensive understanding of regulatory pathways, drug development stages, and clinical research demands.

Chinese testing
Pharmaceutical Market Access Consulting
Pharma and Biotech Innovation

Our services include:

Regulatory strategy and planning to reduce risks and eliminate uncertainty
Accelerated registration pathways to shorten time-to-market streamline the drug development process
End-to-end compliance support to meet regional requirements and safeguard operations
Market access strategies tailored to to maximize value, patient reach, and commercial success.

Whether you’re initiating clinical trials, navigating drug registration, or expanding across Asia Pacific, we deliver targeted solutions and proven results across all stages of development.

Work with Cisema to stay ahead of regulatory trends, reduce time-to-market, and achieve sustainable success across China and the broader Asia-Pacific region.

Discover Our Pharmaceutical Consulting Services

Pharmaceutical Development & Strategy

Drive successful market entry and growth with confidence. Our pharmaceutical regulatory consulting experts support biotech and life sciences companies in streamlining drug development, accelerating approvals, and achieving commercialization through tailored strategies, clinical insights, and end-to-end compliance solutions.

Scientific, Technical & Clinical Due Diligence
Development Strategy & Gap Analysis
Regulatory and Clinical Strategy Development
Health Authority Interaction
Scientific, Medical, Technical & Regulatory Writing

Health Economics & Market Access

Accelerate access across China and Asia Pacific with confidence. Our market access consultants help life sciences companies optimize patient access, navigate pricing and reimbursement challenges, and enable commercial success through real world evidence, health economics, and tailored access strategies.

Market Intelligence
Pricing and Reimbursement (P&R) Landscape Analysis
Strategic Market Entry & Pricing Models
Reimbursement Strategy
Competitive Dynamics Assessment
Stakeholder Engagement & Market Insights

Pharmaceutical Regulatory Affairs

Navigate regulatory complexity across China and Asia Pacific with confidence. Our regulatory affairs consulting experts support life sciences clients with strategic planning, compliant submissions, and local representation to accelerate approvals and ensure market readiness.

Scientific, Technical and Regulatory Strategy
Procedure Management
CMC & Compliance
Health Authority Interaction
Labeling Management & Promotional Material Review
Legal Agent / Domestic Responsible Agent

Pharmaceutical Quality Management & Compliance

Ensure regulatory excellence across China and Asia Pacific with confidence. Our quality management and compliance experts help life sciences organizations strengthen GxP systems, streamline audits, and maintain inspection readiness to safeguard market access and operational performance.

Review, Assessment & Pre-audits of GxP/QMS/SOPs
Ingredient Compliance Analysis
Vendor Audit and Management
Pre-approval Inspection
China & overseas factory audits
Official NMPA Inspection Assistance

Pharmacovigilance

Ensure drug safety and regulatory compliance across China and Asia Pacific with confidence. Our pharmacovigilance consulting experts support life sciences companies in managing risks, meeting evolving safety requirements, and maintaining market authorization through end-to-end PV solutions tailored to local regulations.

Signal Management
Risk Management
Case Safety Report Management
Clinical Trial Safety
Pharmacovigilance System Audit & CAPA
Post-Marketing Surveillance

Why Cisema?

Cisema brings together regional expertise, industry insights, and operational excellence to support pharmaceutical success. We work closely with our clients to address regulatory, strategic, and quality challenges, ensuring timely approvals, sustainable market access, and efficient commercialization. Our consultants are trusted by leaders across the life sciences industry for their depth of experience and commitment to quality outcomes.


We help you:

Prepare your product pipeline for China and the Asia Pacific region
Develop effective strategies aligned with local healthcare policy
Respond quickly to evolving trends and regulatory shifts
Navigate compliance requirements with confidence
Optimize clinical trial processes, data use, and real-world evidence

Whether your focus is innovation, access, or long-term growth, our consulting solutions are built to deliver measurable results.

Pharma and healthcare expertise from the Cisema team

Request a Proposal from Our Pharma Team

Let Cisema help turn your plans into reality.

Request Proposal

Useful Articles

View More

China’s 15th Five-Year Plan: Implications for Drugs, Medical Devices, & Market Access 

China’s 15th Five-Year Plan signals stronger support for innovative drugs, advanced medical devices, reimbursement reform, and NMPA regulatory pathways.

May 8, 2026
China’s 15th Five-Year Plan: Implications for Drugs, Medical Devices, & Market Access 
Chinese flag against a blue sky

China Hyaluronic Acid Registration: A Complete Guide

A complete guide to China hyaluronic acid registration, covering classification, NMPA requirements, and compliance steps for manufacturers.

April 27, 2026
China Hyaluronic Acid Registration: A Complete Guide
China Hyaluronic Acid Registration: A Complete Guide

Malaysia Drug–Medical Device Combination Products: A Guide to Classification & Regulatory Pathways

Learn how Malaysia classifies drug–medical device combination products and how the PMOA determines pathways and compliance responsibilities.

April 23, 2026
Malaysia Drug–Medical Device Combination Products: A Guide to Classification & Regulatory Pathways
Laboratory professional in protective eyewear, hair cover, sterile gown, and blue nitrile gloves examining a filled syringe in a clean laboratory environment.

How Singapore Accelerates ASEAN Market Entry for Medical Devices, Pharma, and Cosmetics

This guide explains Singapore’s HSA regulatory system and why it is a strategic first step for entering Southeast Asian markets with medical devices, pharmaceuticals, and cosmetics.

April 23, 2026
How Singapore Accelerates ASEAN Market Entry for Medical Devices, Pharma, and Cosmetics
Expand into Southeast Asia with Confidence – Singapore as Your Regulatory Gateway

GBA Connect Scheme: Using Real World Data to Support China NMPA Approval

Discover how leveraging Real World Data generated in the Greater Bay Area can accelerate market entry for medical products in China.

April 23, 2026
GBA Connect Scheme: Using Real World Data to Support China NMPA Approval
GBA Connect Scheme: Using Real World Data to Support China NMPA Approval
Previous
Previous

Other Industries We Support

In addition to pharmaceuticals and biotech, we offer consulting services across regulated industries, including medical devices, IVDs, cosmetics, health foods, veterinary products, and other industrial and consumer goods. Our team ensures tailored regulatory compliance strategies, regardless of product category or manufacturing model.

Medical Devices

In-Vitro Diagnostics

Biotech

Cosmetics

Health Foods & Supplements

Veterinary Medicines & Products

Industrial Goods & Consumer Products

Latest Insights

View More

Hong Kong Launches Primary Evaluation Phase 1 for NDAs

Hong Kong introduces Primary Evaluation Phase 1 for NDAs, requiring pathway selection across 3 routes and reshaping drug registration strategy.

May 6, 2026
Hong Kong Launches Primary Evaluation Phase 1 for NDAs
A single Asian scientist in their 30s wearing a lab coat, safety glasses, and nitrile gloves seated at a tidy bench in a modern pharmaceutical laboratory in Hong Kong, calmly reviewing a few printed documents while referencing a simple laptop screen

Hong Kong Clarifies Injectable Products Are Regulated as Pharmaceutical Products Under Cap. 138

Hong Kong confirms injectable products are generally classified as pharmaceutical products under Cap. 138, impacting medical aesthetics and borderline products

May 8, 2026
Hong Kong Clarifies Injectable Products Are Regulated as Pharmaceutical Products Under Cap. 138
Minimalist, well-lit medical aesthetics clinic in Hong Kong. An Asian female doctor in a simple white coat and disposable gloves sits beside a female patient, holding a single unbranded prefilled syringe at chest level.

China April 2026 Reforms Reshape Drug Approval, Pricing, & Access

The reforms introduce new drug pricing rules, clarified conditional approval procedures, and tiered care measures.

May 8, 2026
China April 2026 Reforms Reshape Drug Approval, Pricing, & Access
Chinese scientists gathered around a bottle of medicine

China’s New AI Ethics Measures Increase Scrutiny of High-Impact AI, Including Health-Related Technologies

China’s MIIT and nine ministries introduce a new AI ethics review and services framework establishing tiered oversight, compliance obligations, and governance pathways for AI activities in China.

April 28, 2026
China’s New AI Ethics Measures Increase Scrutiny of High-Impact AI, Including Health-Related Technologies

BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation

BPOM confirms pharmaceutical authorization, GMP oversight, and regulatory authority remain unchanged under the Indonesia–US trade agreement.

April 23, 2026
BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation
Laboratory scientist wearing a lab coat, protective goggles, gloves, and a blue hair cover carefully examining a small vial of liquid in a modern laboratory. A tray of sample vials sits on the bench in front.

NMPA CDE Issues MRCT Benefit-Risk Assessment Guideline

China releases guiding principles for benefit-risk assessment using multi-regional clinical trial data to support global drug development.

April 23, 2026
NMPA CDE Issues MRCT Benefit-Risk Assessment Guideline
Previous
Previous

Get in Touch with Our Pharmaceutical Consultants

Speak to our consultants to learn how our comprehensive services, regulatory guidance, and operational expertise can help you stay ahead in the complex pharmaceutical regulatory environment of China and the Asia Pacific region.

Request Proposal